AGP Picks
View all

DOX Shareholder Alert: Ademi LLP Investigates Claims of Securities Fraud Against Amdocs Limited

DOX’s stock recently dropped more than 30%; Ademi LLP is investigating Amdocs for potential securities fraud.

CLICK HERE TO JOIN

MILWAUKEE, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating possible securities fraud claims against Amdocs (Nasdaq: DOX). The investigation results from inaccurate statements Amdocs may have made regarding its financial statements, business operations and prospects.

Are You a DOX Shareholder?
If you’re losing money on your Amdocs investment, Ademi LLP would like to hear from you to discuss your rights.

You may also contact Guri Ademi at gademi@ademilaw.com or toll-free at 866-264-3995.
There is no cost or obligation to you.

What Is Ademi LLP Investigating?

The Company’s previous claims about loss contingencies, litigations and relationships with customers, and specifically its relationship with Team Mobile.

What Should DOX Shareholders Do?

Contact Ademi LLP to discuss your rights and our investigation. There is no cost or obligation to you.

Guri Ademi
Ademi LLP
Toll Free: (866) 264-3995
Email: gademi@ademilaw.com

About Ademi LLP
Ademi LLP represents investors in shareholder litigation involving mergers, acquisitions, buyouts, and individual shareholder rights.

Attorney advertising. Prior results do not guarantee similar outcomes.

SOURCE: Ademi LLP


Primary Logo

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

LATAM Consumer Weekly

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.